Pfizer evaluates Isogenica’s technology
This article was originally published in Scrip
Pfizer is assessing Isogenica's CIS display technology for its ability to generate therapeutic peptide candidates. Financial details and therapeutic areas of the evaluation agreement were not disclosed. The CIS display technology rapidly identifies peptides, polypeptides and antibodies that bind with high affinity and specificity to any molecular target, making very large gene libraries. Earlier this month, Isogenica granted Centocor Research & Development the non-exclusive right to use the CIS display technology for the discovery of certain therapeutic proteins. Isogenica will receive multi-million pound initial licence fees over the first three years of the agreement and ongoing licence maintenance fees and milestones associated with the clinical development of products discovered through the technology. Dr Kevin FitzGerald, Isogenica's CEO, said that the company normally conducted research for other companies rather than licensing out the platform.
You may also be interested in...
Laura Gonz�lez-Molero will be celebrating her first anniversary as President of Bayer HealthCare Pharmaceuticals, Latin America this month. With Bayer posting total sales of €1.05bnin Latin America in 2014, up 13% over 2013, Ms Gonz�lez-Molero should be pleased with a successful inaugural year. Resolute in her belief that innovation, "part of Bayer's DNA," will determine the company's long-term success in Latin America, rather than growth through acquisition, Ms Gonz�lez-Molero talks to Scrip about her personal ambitions for the company and the region.
A decade since its formation Anvisa, Brazil's medicines regulator, has shaken up the country's framework for ensuring drug quality. Yet the agency's approaches to drug pricing and registration have left some multinationals wanting, reports Sita Shah.
Elan is raising $1.5 billion in bonds to refinance its existing debt and for general corporate purposes, it says.